Observational retrospective study to explore the results and security of Abiraterone in hormone-resistant metastatic prostate cancer patients (HRPCm).
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2015
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Nov 2015 New trial record